ALLUVI: A DETAILED EXPLORATION INTO THE MEDICATION'S PROMISE

Alluvi, formerly LY3414901, represents a noteworthy advancement in metabolic management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist demonstrates remarkable efficacy in early clinical data, with substantial weight loss